AGT103-T

About American Gene Technologies

American Gene Technologies is a private, clinical-stage biotech pioneering gene and cell therapies with a core lentiviral vector platform. Its most advanced program, AGT103-T for an HIV cure, has completed a Phase 1 trial and received FDA Fast Track designation, demonstrating early safety and signals of reservoir reduction. The company is also developing an immuno-oncology approach (ImmunoTox) for solid tumors and a gene therapy for PKU, which holds Orphan Drug status. AGT operates as a platform company aiming to reduce the time and cost of developing new genetic medicines.

About Addimmune

Addimmune, a project within American Gene Technologies, is a clinical-stage biotechnology company focused on developing a one-time functional cure for HIV using a proprietary lentiviral gene therapy platform. Its lead candidate, AGT103-T, is designed to modify a patient's own CD4+ T cells to resist HIV infection and enhance immune control, with initial clinical trials showing promising safety and efficacy signals. The company operates as a private, pre-revenue entity, relying on funding from its parent company and donations to advance its pivotal clinical program aimed at addressing a significant unmet medical need.

Therapeutic Areas